Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Receivables (2022 - 2025)

Verrica Pharmaceuticals has reported Receivables over the past 4 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Receivables at $5.3 million for Q4 2025, up 6783.12% from a year ago — trailing twelve months through Dec 2025 was $5.3 million (up 6783.12% YoY), and the annual figure for FY2025 was $5.3 million, up 6783.12%.
  • Receivables for Q4 2025 was $5.3 million at Verrica Pharmaceuticals, down from $7.0 million in the prior quarter.
  • Over the last five years, Receivables for VRCA hit a ceiling of $10.2 million in Q2 2024 and a floor of $77000.0 in Q4 2024.
  • Median Receivables over the past 4 years was $5.3 million (2025), compared with a mean of $4.9 million.
  • Biggest five-year swings in Receivables: plummeted 98.26% in 2024 and later soared 8233.33% in 2025.
  • Verrica Pharmaceuticals' Receivables stood at $99000.0 in 2022, then surged by 4360.61% to $4.4 million in 2023, then plummeted by 98.26% to $77000.0 in 2024, then skyrocketed by 6783.12% to $5.3 million in 2025.
  • The last three reported values for Receivables were $5.3 million (Q4 2025), $7.0 million (Q3 2025), and $9.2 million (Q2 2025) per Business Quant data.